<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988507</url>
  </required_header>
  <id_info>
    <org_study_id>DRI10382</org_study_id>
    <nct_id>NCT00988507</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
  <acronym>FARM</acronym>
  <official_title>Parallel Group, Double-blind, Randomized Study Assessing the Efficacy, Safety and Pharmacokinetic Profiles of Ferroquine Associated With Artesunate and a Single-blind Dose Level of Ferroquine Alone in a 3-day Treatment of Uncomplicated Malaria Due to Plasmodium Falciparum in an Immune Symptomatic African Adult and Pediatric Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To assess the Day 28 efficacy defined as the percentage of patients with
      no parasitic recrudescence, of 3 treatment groups - 3 dose levels of ferroquine associated
      with artesunate - for a 3-day treatment.

      Secondary objectives:

        -  To assess the efficacy of ferroquine at one dose level alone for a 3-day treatment.

        -  To assess the clinical safety of 4 treatment groups - 3 dose levels of ferroquine
           associated with artesunate and one dose level of ferroquine alone.

        -  To assess pharmacokinetics parameters of ferroquine and its metabolites along sparse
           sampling schedules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall study duration is 64 days, consisting of a screening period (less or equal 1
      day), of a 3-day treatment period during which the patient is hospitalized for a maximum of
      60 hours, and a follow-up period of 61 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to modify the ferroquine development strategy; discontinuation not due to
    safety or activity unexpected findings
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recrudescent infections at D28 in the groups with ferroquine associated with artesunate. Recrudescence is defined as the recurrence of the same original strain of Plasmodium falciparum regardless of clinical symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate at Day 28</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time (Median).</measure>
    <time_frame>up to 63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time (Median)</measure>
    <time_frame>up to 63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recrudescent infections at Day 28 in the ferroquine group in monotherapy</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recrudescent infections at Day 63</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate Clinical and Parasitological Response (ACPR) at D28</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Plasmodium Falciparum Infection</condition>
  <arm_group>
    <arm_group_label>Ferroquine high dose + artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine medium dose + artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine low dose + artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine alone at medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferroquine (SSR97193)</intervention_name>
    <description>Pharmaceutical form: capsule
Route of administration: oral</description>
    <arm_group_label>Ferroquine high dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine medium dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine low dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine alone at medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: capsule
Route of administration: oral</description>
    <arm_group_label>Ferroquine high dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine medium dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine low dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine alone at medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artesunate</intervention_name>
    <description>Pharmaceutical form: tablets
Route of administration: oral</description>
    <arm_group_label>Ferroquine high dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine medium dose + artesunate</arm_group_label>
    <arm_group_label>Ferroquine low dose + artesunate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  3 cohorts enrolled in sequence with data interim review by Data Monitoring Committee
             (DMC) between cohort 1-2 and cohort 2-3

               -  Cohort 1 : Adults &gt; 50 kg or Adolescents &gt;30 kg and age &gt; or = 14 years

               -  Cohort 2 : Children with body weight [30 kg- 15 kg[

               -  Cohort 3 : Children with body weight [15 kg-10 kg]

          -  Age related Body Mass Index (BMI)&gt; or = 5 th percentile.

          -  Presence of body temperature &gt; or = 37.5Â°C or history of fever in the last 24 hours.

          -  Monoinfection with Plasmodium falciparum with parasitemia from 1,000/microL to
             200,000/microL.

          -  Signed Informed Consent Form by the patient (if the patient is &gt; or = age defining
             majority) or by the parents or legal guardian of minor patients (&lt;18 years of age or &lt;
             other age locally defining majority). In addition, participants with capacity for
             writing will sign off on an Assent Form. Patients with no capacity for writing will
             have the Assent Form read. In that case, an impartial witness will certify the
             document was read to the child.

        Exclusion Criteria:

          -  Presence of HBs antigen and of anti-HCV antibodies

          -  Laboratory parameters with clinical significant abnormalities and/or reaching critical
             values : Hemoglobin (&lt; 7g/dl), hematocrit, red blood cell count, white blood cell,
             reticulocytes, platelets, glucose, creatinine, aspartate transferase (AST), alanine
             transferase (ALT &gt; 3 ULN), alkaline phosphatase, total bilirubine &gt; 1.5 ULN.

          -  History or presence of any clinically significant disease or symptoms which might
             confound the interpretation of the safety and efficacy information.

          -  Splenectomized patients.

          -  Presence of criteria for complicated malaria

          -  Patients unable to drink

          -  Breastfeeding patients.

          -  Permanent vomiting.

          -  Female participants with child bearing potential not willing to use an effective
             contraceptive(s) method(s) for the duration of the study (e.g. implants, oral
             contraceptives, some intra-uterine devices or a double barrier method). The need for
             an efficient method will be reminded to the patient and the patient's legal
             guardian(s) by the investigator.

          -  Previous treatment within 5 times the elimination half-life or within the last 14
             days, whichever the longest :

               -  with any anti-malaria agents i.e., quinine, chloroquine, amodiaquine, mefloquine,
                  halofantrine, sufladoxine-pyrimethamine, doxycycline-pyrimethamine, primaquine,
                  artemether, atovaquone, proguanil, lumefantrine,

               -  with an other investigational drug

               -  with 2D6 main substrates

          -  Past or concomitant participation in a study with an anti-malaria vaccine.

          -  Measles vaccine injection within the last 15 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 204001</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 854002</name>
      <address>
        <city>Bobo-Dioulasso 01</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 854003</name>
      <address>
        <city>Nouna</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 854001</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 120001</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 266001</name>
      <address>
        <city>B.P. 118 Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 266002</name>
      <address>
        <city>Libreville</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 404001</name>
      <address>
        <city>Kilifi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 404002</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 834001</name>
      <address>
        <city>Korogwe</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Burkina Faso</country>
    <country>Cameroon</country>
    <country>Gabon</country>
    <country>Kenya</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

